Juan M. Hincapie-Castillo, PharmD, PhD

About

Juan M. Hincapie-Castillo, Pharm.D, M.S., Ph.D. is an assistant professor of epidemiology at the University of North Carolina at Chapel Hill. Prior to joining UNC, he was an assistant professor of Pharmaceutical Outcomes & Policy at the University of Florida. He is a graduate from the University of Florida College of Pharmacy where he received the degrees of Doctor of Pharmacy, Master of Science in Pharmaceutical Sciences, and Ph.D. with a concentration in pharmacoepidemiology. He is the recipient of the 2020 New Investigator Award from the American Association of Colleges of Pharmacy and the 2020 Emerging Leader Award from the International Society for Pharmacoepidemiology (ISPE). His research is at the intersection of legal and pharmacoepidemiology, where he leverages large real-world data sources to evaluate and promote evidence-based policymaking. His primary focus is on improving prescribing policies and the provision of equitable pain management and safe psychotropic medication use. Dr. Hincapie-Castillo is a consultant for the FDA’s Drug Safety and Risk Management Advisory Committee (DSaRM). In 2021, he was appointed as a Research Fellow for the Center for Public Health Law Research (CPHLR) at Temple University. He currently serves as President of the Board of Directors and member of the Science & Policy Advisory Board for the National Pain Advocacy Center. 

Juan Hincapie-Castillo in the Gillings News

Honors and Awards

Research Fellow
2021, Center for Public Health Law Research at Temple University

Emerging Leader
2020, International Society for Pharmacoepidemiology

New Investigator Award
2020, American Association of Colleges of Pharmacy

Keynote Speaker for Doctoral & Master's Commencement Summer
2020, University of Florida College of Pharmacy

Research Activities

Pharmacoepidemiology

Legal Epidemiology

Health Services Research

Drug Utilization Research

Pain Management

Opioids

Service Activities

Associate Editor, Pharmacoepidemiology and Drug Safety Journal, 2021-Present

Science and Policy Advisor, National Pain Advocacy Center, 2020-Present 

Consultant, FDA’s Drug Safety and Risk Management Advisory Committee (DSaRM), 2020-Present

Key Publications

The effects of the Florida’s Opioid Restriction Law for Acute Pain on the Utilization of Prescription NSAID Medications. Keshwani S, Grande I, Maguire M, Vouri S, Goodin A, Hincapie-Castillo JM. (2021). JAMA Netw Open, 4(6).

Effects of Food and Drug Administration Removal of Indications for Use of Oral Quinolones. Tran PT, Antonelli P, Hincapie-Castillo JM, Winterstein A. (2021). JAMA Intern Med, 181(6), 808-816.

Changes in Prescribing by Provider Type Following a State Prescription Opioid Restriction Law. Valdes I, Possinger M, Hincapie-Castillo JM, Goodin A, Dewar M, Sumfest J, Vouri SM. (2021). J Gen Intern Med.
View publication

Impact of Injectable Opioid Restrictions during a Critical Drug Shortage Period: Interrupted Time Series for Institutional Opioid Utilization. Brokenshire S, Lemon SJ, Staley B, Voils A, Hincapie-Castillo JM. (2021). Pain Med, 22(2), 203-211.

Purchasing Drugs Abroad among US Cancer Survivors: Analysis of National Health Interview Survey 2011-2018. Hong Y, Xie Z, Gutter M, Odedina F, Hincapie-Castillo JM (2020). Am J Prev Med., S0749-3797(20), 30511-0.

Changes in Opioid Use After Florida’s Restriction Law for Acute Pain Prescriptions. Hincapie-Castillo JM, Goodin A, Possinger M, Usmani S, Vouri S. (2020). JAMA Netw Open, 3(2).

Education